JADO reports clinical proof of concept with RAFT modulator in atopic dermatitis
21-Feb-2008 -
JADO Technologies GmbH, developer of RAFT intervention therapeutics, announced positive results from a Phase IIa clinical trial of its lead RAFT modulator TF002 in patients with severe atopic dermatitis. TF002, a topical formulation of miltefosine, exerts its anti-inflammatory activity via RAFT ...
allergic diseases
atopic dermatitis
atrophy
+4